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Summary
Background Bronchiectasis is characterised by chronic cough, sputum production, and recurrent chest infections. 
Pathogenesis is poorly understood, but excess neutrophilic airway inﬂ ammation is seen. Accumulating evidence 
suggests that statins have pleiotropic eﬀ ects; therefore, these drugs could be a potential anti-inﬂ ammatory treatment 
for patients with bronchiectasis. We did a proof-of-concept randomised controlled trial to establish if atorvastatin 
could reduce cough in patients with bronchiectasis.
Methods Patients aged 18–79 years were recruited from a secondary-care clinic in Edinburgh, UK. Participants had 
clinically signiﬁ cant bronchiectasis (ie, cough and sputum production when clinically stable) conﬁ rmed by chest CT 
and two or more chest infections in the preceding year. Individuals were randomly allocated to receive either high-
dose atorvastatin (80 mg) or a placebo, given orally once a day for 6 months. Sequence generation was done with a 
block randomisation of four. Random allocation was masked to study investigators and patients. The primary 
endpoint was reduction in cough from baseline to 6 months, measured by the Leicester Cough Questionnaire (LCQ) 
score, with a lower score indicating a more severe cough (minimum clinically important diﬀ erence, 1·3 units). 
Analysis was done by intention-to-treat. The trial is registered with ClinicalTrials.gov, number NCT01299181.
Findings Between June 23, 2011, and Jan 30, 2011, 82 patients were screened for inclusion in the study and 22 were 
excluded before randomisation. 30 individuals were assigned atorvastatin and 30 were allocated placebo. The change 
from baseline to 6 months in LCQ score diﬀ ered between groups, with a mean change of 1·5 units in patients allocated 
atorvastatin versus –0·7 units in those assigned placebo (mean diﬀ erence 2·2, 95% CI 0·5–3·9; p=0·01). 12 (40%) of 
30 patients in the atorvastatin group improved by 1·3 units or more on the LCQ compared with ﬁ ve (17%) of 30 in the 
placebo group (diﬀ erence 23%, 95% CI 1–45; p=0·04). Ten (33%) patients assigned atorvastatin had an adverse event 
versus three (10%) allocated placebo (diﬀ erence 23%, 95% CI 3–43; p=0·02). No serious adverse events were recorded.
Interpretation 6 months of atorvastatin improved cough on a quality-of-life scale in patients with bronchiectasis. 
Multicentre studies are now needed to assess whether long-term statin treatment can reduce exacerbations.
Funding Chief Scientist’s Oﬃ  ce.
Copyright © Mandal et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Bronchiectasis is a chronic disabling respiratory disorder 
characterised by cough, sputum production, and 
recurrent chest infections. It is regarded as an orphan 
disease, not because of its rarity but because of the 
paucity of randomised trial data: 133 trials were identiﬁ ed 
for bronchiectasis in a recent PubMed search, versus 
8748 for asthma.1 The true incidence of bronchiectasis in 
the modern era of chest CT is not known. At our 
institution in Edinburgh, UK, we provide secondary care 
for more than 750 patients with bronchiectasis, from 
a total population of about 490 000. Patients frequently 
use primary-care and secondary-care resources through 
consultations, attendance at accident and emergency 
units, and admissions.
The pathogenesis of bronchiectasis is poorly understood, 
but pulmonary pathological ﬁ ndings show excess 
neutrophilic airway inﬂ ammation. However, more than 
two-thirds of patients are infected chronically with 
potential pathogenic organisms.2 The ampliﬁ ed level of 
neutrophilic airway inﬂ ammation leads to damage of the 
bronchial wall, paradoxically promoting more airways 
inﬂ ammation and bacterial infection, and a vicious cycle is 
seen.3 Markers of systemic inﬂ ammation—eg, C-reactive 
protein—are raised in patients with bronchiectasis and 
correlate directly with disease severity and inversely with 
lung function and quality of life in stable-state 
bronchiectasis.4 Long-term evidence-based treatments for 
the disorder are scarce; chest physiotherapy and continued 
use of antibiotics are current therapeutic approaches. 
Concerns have been raised about use of long-term 
antibiotics because of resistance, side-eﬀ ects, and health-
care-associated infections. In view of these concerns, and 
the excess inﬂ ammatory response in the airways, 
investigation is underway into the eﬃ  cacy of anti-
inﬂ ammatory treatments.
Statins have pleiotropic eﬀ ects, including modulation 
of the innate and adaptive immune systems and 
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reduction of inﬂ ammation.5,6 For example, statins 
attenuate neutrophil recruitment in animal and human 
experimental systems of sterile inﬂ ammation.7,8 In 
murine models of pulmonary infection with 
Staphylococcus aureus, high-dose statin treatment 
enhanced the formation of extracellular DNA traps by 
phagocytes within the lung and protected against 
dissemination of infection.9,10 Boyd and colleagues11 
reported that prolonged high-dose simvastatin had a 
strong dose-dependent eﬀ ect on protection against 
Streptococcus pneumoniae in a mouse model of lung 
infection, indicated by reduced neutrophil inﬁ ltration, 
maintenance of vascular integrity, and diminished 
chemokine production. Furthermore, ﬁ ndings of 
observational studies in individuals with community-
acquired pneumonia showed a reduction of 30-day 
mortality in patients who were also receiving statins.12
We postulated that long-term statin treatment would 
improve symptoms in patients with bronchiectasis by 
reducing neutrophilic airway inﬂ ammation. The aim of 
our proof-of-concept study was to establish if atorvastatin 
could reduce cough, a key feature in patients with 
bronchiectasis. We chose atorvastatin because it is a 
potent statin for reduction of cholesterol and has a low 
side-eﬀ ect proﬁ le, and we administered the drug at the 
maximum dose because our study was proof-of-concept 
and use of the maximum dose avoids the need to repeat 
the study at diﬀ erent doses.
Methods
Study population
We recruited patients aged 18–79 years with clinically 
signiﬁ cant bronchiectasis who were receiving treatment 
at the South East of Scotland Bronchiectasis Clinic, based 
at the Royal Inﬁ rmary, Edinburgh, UK. Inclusion criteria 
were cough and sputum production when clinically 
stable; two or more chest infections in the preceding 
year; and bronchiectasis conﬁ rmed on chest CT. For 
diagnosis on CT, bronchial dilatation had to be present 
(bronchus:arterial ratio >1).
We excluded current smokers or former smokers who 
had stopped smoking less than 1 year previously, those 
with a greater than 15 pack-year history, or those with 
predominant emphysema on CT scan; people with cystic 
ﬁ brosis; individuals with active allergic broncho-
pulmonary aspergillosis; patients with active tuberculosis; 
people with poorly controlled asthma; women who were 
pregnant or breastfeeding; individuals with a known 
allergy to statins; those currently on statins or who 
had used them within the previous year; people with 
active malignant disease; individuals with chronic liver 
disease; and patients on long-term oral macrolides 
(because of the known interaction with statins). We also 
excluded people who had chronic colonisation with 
Pseudomonas aeruginosa (deﬁ ned as two or more isolates 
of P aeruginosa while clinically stable in the 6 months 
before the study), because these individuals have more 
severe disease13,14 and the objective of our study was to 
investigate the eﬀ ects of atorvastatin in patients with less 
severe bronchiectasis.
We obtained ethics approval from the South East of 
Scotland research ethics committee. All patients gave 
written informed consent.
Randomisation and masking
We randomly allocated patients to receive either high-
dose atorvastatin (80 mg) or a placebo (lactose), given 
orally once a day for 6 months. The placebo was not 
matched to atorvastatin in appearance. Tayside 
Pharmaceuticals (NHS Tayside, UK) generated the 
random allocation sequence, which was done with a block 
randomisation of four. The Bronchiectasis Clinic’s 
pharmacy dispensed study drugs directly to patients; 
therefore, allocation concealment was maintained at all 
times from the study investigators.
Outcomes
The primary outcome was a reduction in cough at 
6 months compared with baseline, measured by the 
Leicester Cough Questionnaire (LCQ) score.15 We have 
validated use of this scoring system in bronchiectasis.16 
Secondary outcomes included: forced expiratory volume 
in 1 s (FEV1), forced vital capacity (FVC), and the FEV1:FVC 
ratio; the incremental shuttle-walk test;17 qualitative 
and quantitative sputum bacteriology; frequency of 
exacerbations; health-related quality of life, assessed by 
the St George’s Respiratory Questionnaire (SGRQ);18 
assessment of sputum neutrophil numbers and 
apoptosis; neutrophil activation in the airway, measured 
by sputum myeloperoxidase, free elastase activity, and 
interleukin 8 (a key neutrophil chemoattractant in 
bronchiectasis);19 systemic inﬂ ammation, measured by 
white-blood-cell count, concentrations of C-reactive 
protein, and the erythrocyte sedimentation rate; other 
markers of systemic inﬂ ammation, including amounts of 
interleukins 1β, 6, 8, 10, and 12p70, and tumour necrosis 
factor α; and safety of treatment.
Procedures
We did all assessments at baseline and 6 months. 
At 3 months, we checked LCQ scores (data presented) 
and blood measurements and adherence to treatment 
(data available on request).
We assessed cough with the LCQ. This questionnaire 
is a 19-item, self-completed, quality-of-life measure of 
chronic cough, with scores from 3 to 21 (a lower score 
indicates more severe cough). The minimum clinically 
important diﬀ erence in LCQ score is 1·3 units. The LCQ 
is repeatable over 6 months in stable disease (intra-
class correlation coeﬃ  cient 0·96, 95% CI 0·93–0·97; 
p<0·0001).16 
We measured prebronchodilator FEV1, FVC, and 
FEV1:FVC by spirometry then did an incremental shuttle-
walk test—an externally paced, 10 m, ﬁ eld-walking test 
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incorporating an assessment of dyspnoea before and after, 
with results recorded on the Borg scale (a rating of 
perceived exertion).17 We assessed health-related quality 
of life with the SGRQ.18 This questionnaire is a 50-item 
self-administered test with a total score ranging from 
0 to 100 (a higher score indicates poorer health-related 
quality of life). The minimum clinical important diﬀ erence 
in SGRQ score is 4 units.
We induced sputum with hypertonic (3%) saline for 
10 min20 and gathered samples for bacteriological 
analysis and neutrophil assessments. We determined 
every sample as suitable for processing if more than 
25 polymorphonuclear leucocytes and fewer than 
ten squamous cells were present on Gram stain with 
low-power magniﬁ cation (×20). We used 1 mL of the 
sputum sample for qualitative and quantitative micro-
biological analyses. Brieﬂ y, we homogenised sputum and 
liqueﬁ ed it with an equal volume of dithiothreitol. 
To achieve dilution factors of 10–¹ to 10–⁴, we serially 
diluted the liquid samples with sterile 0·85% saline. 
We inoculated plates of pseudomonas isolation agar 
(Difco; BD Biosciences, Oxford, UK), chocolate blood 
agar containing bacitracin (Oxoid, Basingstoke, UK), 
and horse blood agar (Oxoid) with 100 μL of each 
dilution and incubated plates at 37°C for 48 h. 
We counted colonies of pathogens to ascertain the 
sputum bacterial density (expressed as log10 colony-
forming units [cfu] per mL).
We divided the remainder of the sputum sample 
equally into two portions. To assess total cell numbers, 
we treated one part with 0·1% dithiothreitol, washed the 
sample twice with phosphate-buﬀ ered saline, centrifuged 
it at 2000 g for 10 min at 4°C, and ﬁ ltered the sample 
once, then did cytocentrifugation at 75 g for 3 min at 
room temperature. We calculated cell-diﬀ erential counts 
by counting 400 cells per sample after cytocentri-
fugation.21 We conﬁ rmed apoptosis by the colour and 
shape change of the neutrophil nuclei on cytospins 
(a method to concentrate cells) of sputum samples, as 
seen under the microscope (magniﬁ cation ×1000; 
ﬁ gure 1). The second portion was ultracentrifuged at 
750 g for 90 min at 4°C.22 The colloidal solution phase 
was stored at –70°C until needed for analysis of the 
activity of myeloperoxidase, free neutrophil elastase, 
and interleukin 8. We measured myeloperoxidase activity 
with a chromogenic substrate assay23 and free 
elastase activity by spectrophotometry with a synthetic 
substrate (methoxysuccinyl-Ala-Ala-Pro-Val paranitro-
anilide; Sigma, Gillingham, UK),22,24 and we assayed 
interleukin 8 using commercially available speciﬁ c 
ELISAs (R&D Systems, Oxford, UK).
We took 30 mL of venous blood to obtain a full-blood 
count; to measure the erythrocyte sedimentation rate; to 
ascertain amounts of C-reactive protein, urea, electrolytes, 
and creatine kinase; and to do liver-function tests. 
We centrifuged 5 mL of blood at 750 g for 10 min, collected 
the supernatant, and stored it at –70°C until it was needed 
for measurement of amounts of proinﬂ ammatory and 
anti-inﬂ ammatory cytokines and chemo attractants by 
cytometric bead array (BD Biosciences).
We assessed patients for the presence or absence of 
side-eﬀ ects at all study visits. If activity of alanine 
aminotransferase was greater than ﬁ ve times the normal 
value, or concentrations of creatine kinase were greater 
than three times the upper limit of normal, we stopped 
the assigned study treatment. We recorded all side-eﬀ ects 
Figure 1: Neutrophil apoptosis after treatment with atorvastatin
Neutrophils (per 400 cells counted) are visualised by microscopy in a sample of 
sputum from a patient after 6 months of treatment with atorvastatin. 
Apoptotic neutrophils are indicated by arrows. Magniﬁ cation ×1000.
Figure 2: Trial proﬁ le
*Six patients discontinued for the following reasons: alanine aminotransferase 
level greater than ﬁ ve times the normal value (n=1); diarrhoea (n=1); headache 
and diarrhoea (n=2); headache (n=1); other reasons (n=1). †One patient 
discontinued for other reasons. 
30 atorvastatin 80 mg once a day 30 placebo
24 completed treatment*
30 included in the primary 
 outcome analysis
24 analysed for secondary 
 endpoints
 24 for exacerbations
 24 for sputum-cell counts
29 completed treatment†
30 included in the primary 
 outcome analysis
29 analysed for secondary 
 endpoints
 29 for exacerbations
 28 for sputum-cell counts
60 randomly assigned
82 assessed for eligibility
22 excluded
 14 did not meet inclusion 
   criteria
  6 declined to participate 
  2 other reasons 
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on a patient diary card. We deﬁ ned exacerbations 
according to British Thoracic Society guidelines25 and 
treated them according to baseline sputum bacteriological 
ﬁ ndings and administered 14 days of oral antibiotic 
treatment. We did not use macrolides because of the 
known interaction with statins.
Statistical analysis
We calculated the required sample size per group with a 
two-sided two-sample test with 5% level of signiﬁ cance 
and 90% power. We needed to detect a change of 1·3 units 
in the LCQ (which is the accepted minimum clinically 
important diﬀ erence). Accounting for dropouts, we 
aimed to enrol 30 patients to each group.
We analysed the primary endpoint by intention-to-treat 
and used a modiﬁ ed intention-to-treat analysis for 
secondary endpoints. For demographic and clinical 
variables, we presented data as median (IQR) for 
continuous variables and number (%) for categorical 
variables, unless otherwise stated. We calculated the 
change from baseline to 3 months and to 6 months in the 
LCQ by unpaired t test, between patients assigned 
atorvastatin versus those allocated placebo (data were 
normally distributed). To compare the proportion of 
patients with either clinical improvement (measured by 
the LCQ) or quality-of-life gains (measured by the SGRQ), 
we did a binomial test and presented diﬀ erences as a 
percentage with accompanying 95% CI. We compared 
categorical data between groups with the χ² test. 
We judged p values less than 0·05 signiﬁ cant. 
We analysed all data with SAS, version 9.2.
This study is registered with ClinicalTrials.gov, number 
NCT01299181.
Role of the funding source
The funding source had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between June 23, 2011, and Jan 30, 2013, 82 patients were 
assessed for inclusion in the study and 22 were excluded 
(ﬁ gure 2). 60 individuals were randomised to receive 
treatment: 30 were assigned active treatment with high-
dose atorvastatin (80 mg) and 30 were allocated placebo.
At baseline, mean LCQ scores and other variables were 
comparable between treatment groups (table 1). 
At 6 months, a signiﬁ cant increase (improvement) in 
LCQ score was seen in patients allocated atorvastatin. 
The mean change in LCQ score from baseline to 
6 months in the atorvastatin group was 1·5 units, versus 
–0·7 units in the placebo group (mean diﬀ erence 2·2, 
95% CI 0·5–3·9; p=0·01; ﬁ gure 3). 12 (40%) of 
30 patients allocated atorvastatin had a 1·3 units or more 
improve ment in the LCQ compared with ﬁ ve (17%) of 30 
in the placebo group (diﬀ erence 23%, 95% CI 1–45; 
p=0·04). At 3 months, the mean change in LCQ score 
from baseline also diﬀ ered between groups, with a 
signiﬁ cant improvement noted in the atorvastatin group 
(mean change 2·1 units in the atorvastatin group vs –1·1 
units in the placebo group; mean diﬀ erence 3·3, 
95% CI 0·9–5·6; p=0·006).
Atorvastatin (n=30) Placebo (n=30)
Age (years) 60·2 (10·7) 59·1 (11·4)
Women 17 (57%) 14 (47%)
Smoking status .. ..
Never 26 (87%) 18 (60%)
Former 4 (13%) 12 (40%)
Body-mass index (kg/m²) 28·8 (8·0) 28·1 (6·3)
Body-mass index >30 kg/m² 11 (37%) 10 (33%)
Cause of bronchiectasis .. ..
Idiopathic 21 (70%) 21 (70%)
Post infection 4 (13%) 4 (13%)
Autoimmune disease 4 (13%) 4 (13%)
Inﬂ ammatory bowel disease 1 (3%) 0
IgG2 deﬁ ciency 0 1 (3%)
Ischaemic heart disease 2 (7%) 1 (3%)
Asthma 19 (63%) 17 (57%)
Previous malignant disease 1 (3%) 1 (3%)
Diabetes mellitus 1 (3%) 1 (3%)
Spirometry .. ..
FEV1 (L) 2·1 (0·8) 2·2 (0·9)
Predicted FEV1 (%) 78·3 (23·8) 73·9 (24·5)
FVC (L) 3 (1·1) 3·2 (1·1)
Predicted FVC (%) 94·8 (22·8) 86·4 (25·6)
FEV1:FVC (%) 69 (0·13) 69·6 (0·12)
Markers of systemic inﬂ ammation .. ..
White-cell count (× 10⁹ cells per L) 7·2 (2·2) 6·7 (1·9)
Neutrophils (× 10⁹ cells per L) 4·3 (1·9) 3·9 (1·1)
Erythrocyte sedimentation rate (mm/h) 15·1 (11·7) 14·8 (10·7)
C-reactive protein (mg/L)* 9·9 (15·5) 6·4 (7·7)
Cholesterol (mmol/L) 5·1 (1·1) 5 (0·9)
Sputum microbiology† .. ..
Potentially pathogenic microorganisms 17 (57%) 12 (40%)
Mixed normal ﬂ ora 13 (43%) 17 (57%)
No sputum produced 0 1 (3%)
Other pretreatment drugs .. ..
Inhaled corticosteroids 22 (73%) 18 (60%)
Oral steroids 0 2 (7%)
Long-term antibiotic for chest (penicillin) 1 (3%) 1 (3%)
Diabetes mellitus requiring insulin 0 0
LCQ score (units) 13·1 (4·0) 15·1 (4·4)
Data are mean (SD) or number of patients (%). Data for markers of systemic inﬂ ammation are missing for three 
patients, and microbiological data are missing for one patient. FEV1=forced expiratory volume in 1 s. FVC=forced vital 
capacity. LCQ=Leicester Cough Questionnaire. *Non-SI units were used for analyses; SI units for C-reactive protein are 
(atorvastatin vs placebo) 0·3 (0·5) mmol/L vs 0·19 (0·2) mmol/L. †Microorganisms isolated at baseline (atorvastatin vs 
placebo): Haemophilus inﬂ uenzae (8 [27%] vs 6 [20%]); Streptococcus pneumoniae (4 [13%] vs 1 [3%]); Staphylococcus 
aureus (3 [10%] vs 2 [7%]); other enteric Gram-negative organisms (3 [10%] vs 2 [7%]); Pseudomonas aeruginosa (2 [7%] 
vs 0); Moraxella catarrhalis (0 vs 1 [3%]). Some patients isolated more than one organism.
Table 1: Baseline characteristics
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Two patients in the atorvastatin group isolated 
P aeruginosa at baseline but they were not chronically 
infected with the microorganism. Haemophilus inﬂ uenzae 
was the most common colonising organism in both 
groups at baseline (table 1). At the end of treatment, 
19 (63%) of 30 patients were colonised with micro-
organisms in the atorvastatin group (17 [57%] at baseline) 
versus 12 (40%) of 30 in the placebo group (12 [40%] at 
baseline). No signiﬁ cant diﬀ erence in bacterial load was 
recorded from baseline to 6 months in each treatment 
group. The mean change in bacterial load after 6 months 
of treatment was –2·9 × 10⁷ (SD 1·3 × 10⁷) cfu per mL in the 
atorvastatin group versus 1·9 × 10⁷ (1·2 × 10⁷) cfu per mL in 
the placebo group.
24 patients in the atorvastatin group completed the 
study versus 29 in the placebo group. These patients 
were included in the modiﬁ ed intention-to-treat 
analysis of secondary endpoints (table 2). After 
6 months, fewer viable neutrophils in sputum and 
more apoptotic neutrophils (ﬁ gure 1) were counted in 
the atorvastatin group. In the placebo group, little 
change from baseline was seen. Furthermore, the 
median change in the number of eosinophils, basophils, 
or monocytes in sputum did not diﬀ er between active 
and placebo groups. With respect to inﬂ ammatory 
markers in sputum, the median change over 6 months 
in the amount of interleukin 8 or the activity of 
myeloperoxidase or free elastase was similar between 
the atorvastatin and placebo groups (table 2).
Baseline spirometry ﬁ ndings were not altered at 
6 months, and no diﬀ erence was noted between 
groups in FEV1, FVC, or FEV1:FVC (table 2). Exercise 
capacity was extended at 6 months in patients 
assigned atorvastatin, with a median increase of 35 m 
(IQR –10 to 95) compared with no escalation in distance 
in the placebo group. 
With respect to systemic inﬂ ammation, at 6 months, 
the concentration of interleukin 8 in the atorvastatin 
group decreased from baseline amounts. However, 
atorvastatin had no eﬀ ect on amounts of interleukins 1β, 
6, 10, or 12p70, or tumour necrosis factor α (data not 
shown). At 6 months, the leucocyte count, total neutrophil 
count, and the erythrocyte sedimentation rate were 
comparable with baseline levels in both the placebo and 
active treatment groups (table 2). However, C-reactive 
protein levels fell from baseline to 6 months in patients 
allocated atorvastatin. Independent of the C-reactive 
protein response, patients assigned atorvastatin had 
an increased LCQ score at 6 months (table 2).
Eight (33%) of 24 patients assigned atorvastatin had 
two or more exacerbations compared with 16 (55%) of 
29 in the placebo group (relative risk ratio 0·6, 
95% CI 0·3–1·2). Furthermore, ﬁ ve (21%) of 24 patients 
on atorvastatin had three or more exacerbations compared 
with ten (34%) of 29 in the placebo group (0·6, 0·2–1·5). 
A mild improvement in SGRQ scores was noted at 
6 months in patients allocated atorvastatin (median 
1·3 unit decrease), but this change did not meet the 
accepted minimum clinically important diﬀ erence of a 
4-unit reduction (table 2). Subscores of the SGRQ did not 
diﬀ er between baseline and 6 months (data not shown).
Routine blood analyses showed no signiﬁ cant 
diﬀ erences between treatment groups with respect to 
mean changes over 6 months in urea, creatinine, 
alanine aminotransferase, or creatine kinase. However, 
the change in cholesterol from baseline to 6 months 
diﬀ ered between groups, with patients allocated 
atorvastatin having a greater drop in concentration 
than those assigned placebo (mean diﬀ erence –1·40, 
95% CI –1·77 to –1·02; p<0·0001; table 2).
Using the change in cholesterol concentration from 
baseline to 6 months as an indicator of adherence 
to treatment, a post-hoc stratiﬁ ed analysis was done. 
In two of 29 patients assigned placebo, the amount of 
cholesterol fell by 1 mmol/L or more over 6 months, 
whereas in the atorvastatin group, 15 of 24 individuals 
had such a reduction. Within this subgroup of 
patients with a 1 mmol/L or more fall in cholesterol 
over 6 months, the 6-month change in LCQ score 
diﬀ ered between treatment groups (diﬀ erence 2·2, 
95% CI 0·4–3·9; p=0·016).
Of patients assigned atorvastatin, 26 were never-
smokers and four were former smokers (table 1). 
All four former smokers dropped out of the study; 
therefore, no analysis could be done of this subgroup 
because of a paucity of comparative data from baseline to 
6 months. Subanalyses of data for never-smokers were 
done in both groups; an improvement over 6 months 
in LCQ scores was detected in ten (38%) of 26 patients 
in the atorvastatin group versus two (11%) of 18 in the 
placebo group (1·4 units vs 0·2 units; diﬀ erence 34%, 
95% CI 13–57; p=0·04).
Ten (33%) of 30 patients in the atorvastatin group had 
an adverse event compared with three (10%) of 30 in the 
placebo group (diﬀ erence 23%, 95% CI 3–43; p=0·02; 
table 3). No serious adverse events were reported. 
Two patients who were assigned atorvastatin developed 
leg pain in the ﬁ rst week of starting treatment, but this 
pain subsided in the second week for both individuals. 
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Figure 3: Reduction of cough, measured by Leicester Cough Questionnaire
LCQ=Leicester Cough Questionnaire. (A) Atorvastatin group. (B) Placebo group.
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One patient in the atorvastatin group and two in the 
placebo group had raised creatine kinase concentrations 
while on treatment (less than three times the upper limit 
of normal), which was detected 3 months after starting 
treatment. Repeat measurements were taken in these 
patients after 1 week and the amount of creatine kinase 
had either fallen or had returned to normal levels. 
No patients had to withdraw from the study because of 
high creatine kinase concentrations. In the atorvastatin 
group, one person developed headache while on 
treatment and had to withdraw from the study, and 
diarrhoea was reported in another patient in this 
group within 1 week of starting atorvastatin, leading to 
discontinuation because the diarrhoea persisted. 
A further two patients in the atorvastatin group developed 
both diarrhoea and headache while on treatment; both 
withdrew from the study because symptoms persisted. 
One individual in each group developed abdominal 
discomfort a week after starting treatment, which 
improved spontaneously and they did not need to stop 
treatment. At 3 months, one patient assigned atorvastatin 
had a concentration of alanine aminotransferase of 
5∙5 μkat/L, which was greater than ﬁ ve times the normal 
value; they were withdrawn from the study. Levels of 
alanine aminotransferase in this individual had returned 
to normal when checked 3 days after stopping treatment. 
One patient allocated ator vastatin developed haematuria 
during the ﬁ rst week of study treatment; however, the 
individual was known to have renal calculi and 
subsequently underwent lithotripsy for the renal calculi; 
study treatment continued. All patients had normal renal 
function throughout the study, when measured at 
baseline and 6 months (table 2).
Discussion
The ﬁ ndings of our proof-of-concept study show that 
high-dose atorvastatin for 6 months can signiﬁ cantly 
reduce cough (ie, increase the score on the LCQ) in 
patients with bronchiectasis. Our study was powered to 
detect a change in the LCQ of 1·3 units. The primary 
endpoint was achieved, conﬁ rming that our ﬁ ndings are 
robust, despite the small size of the study.
In addition to reduction of cough, markers of systemic 
inﬂ ammation—eg, interleukin 8 and C-reactive protein—
were diminished with atorvastatin. Furthermore, the 
number of apoptotic airway neutrophils was ampliﬁ ed 
with a statin, whereas the total number of neutrophils in 
sputum fell. Exercise tolerance also increased with use of 
Atorvastatin (n=24) Placebo (n=29)
Sputum diﬀ erential count (per 400 cells counted)*
Apoptotic neutrophils 5·5 (0·0 to 15·0) 0·5 (0·0 to 3·0)
% diﬀ erence of apoptotic neutrophils 15·1 (3·0) –1·4 (0·8)
Viable neutrophils –32·5 (–88·5 to 1·5) –0·5 (–25 to 5)
% diﬀ erence of viable neutrophils –19·5 (5·0) 1·4 (0·6)
Basophils 0·0 (0·0 to 0·0) 0·0 (0·0 to 0·0)
Eosinophils 0·0 (0·0 to 0·0) 0·0 (–0·5 to 1·0)
Monocytes –1·0 (–2·5 to 1·0) 0·0 (0·0 to 2·0)
Sputum inﬂ ammatory markers*
Interleukin 8 (pmol/L) 390 (–1487 to 1651) 399 (–479 to 1155)
Myeloperoxidase (pmol/L) 0 (–13 to 50) 0 (–32 to 86)
Neutrophil elastase (pmol/L) 0 (–980 to 280) 0 (–1588 to 553)
Spirometry
FEV1 (L) –0·01 (–0·13 to 0·13) 0·06 (–0·06 to 0·17)
FVC (L) –0·08 (–0·30 to 0·13) –0·07 (–0·34 to 0·20)
FEV1/FVC 0·01 (–0·02 to 0·07) 0 (–0·04 to 0·07)
Exercise capacity (shuttle-walk test)
Distance walked (m) 35 (–10 to 95) 0 (–20 to 40)
Exacerbations (n)
0 6 (25%) 9 (31%)
1 10 (42%) 4 (14%)
2 3 (13%) 6 (21%)
≥3 5 (21%) 10 (34%)
Systemic inﬂ ammation†
White-blood cells (×10⁹ cells per L) –0·4 (–0·7 to 0·5) –0·1 (–0·8 to 0·9)
Neutrophils (×10⁹ cells per L) –0·0 (–0·4 to 0·4) –0·1 (–0·5 to 0·9)
Lymphocytes (×10⁹ cells per L) –0·1 (–0·3 to 0·1) –0·0 (–0·2 to 0·1)
Monocytes (×10⁹ cells per L) –0·0 (–0·1 to 0·1) –0·1 (–0·1 to 0·0)
Eosinophils (×10⁹ cells per L) –0·1 (–0·1 to 0·0) –0·0 (–0·1 to 0·1)
C-reactive protein (mg/L)‡ –1·0 (–6·0 to 0·0) 0 (–3·0 to 1·0)
Erythrocyte sedimentation rate (mm/h) –1·0 (–8·0 to 1·0) 1·0 (–4·0 to 6·0)
Interleukin 8 (pmol/L) –2·9 (–0·6 to 28·8) 0·5 (–6·5 to 10·8)
Routine blood tests†
Alanine aminotransferase (μkat/L) 0·03 (–0·09 to 0·09) –0·02 (–0·09 to 0·07)
Creatine kinase (μkat/L) –0·09 (–0·8 to 0·4) –0·3 (–1·0 to –0·05)
Cholesterol (mmol/L) –1·3 (–2·1 to –0·6) 0·0 (–0·2 to 0·4)
Urea (mmol/L) 0·3 (–0·9 to 1·1) 0·2 (–0·8 to 0·9)
Creatinine (mmol/L) –1·0 (–4·0 to 3·0) –1·0 (–4·0 to 7·0)
SGRQ score (units) –1·3 (–4·2 to 0·0) 0·0 (–1·6 to 1·1)
LCQ score (units), analysed by C-reactive protein response†
C-reactive protein reduction ≥1 mg/L‡ 2·5 (0·1 to 3·8) 0·1 (–0·2 to 0·4)
No response, or C-reactive protein <1 mg/L‡ 0·55 (–0·2 to 2·2) –1·3 (–4·9 to 0·0)
Data are median (IQR) change from baseline to 6 months. FEV1=forced expiratory volume in 1 s. FVC=forced vital 
capacity. LCQ=Leicester Cough Questionnaire. SGRQ=St George’s Respiratory Questionnaire. *Data missing for one 
patient. †Data missing for three patients. ‡1 mg/L=0·03 mmol/L.
Table 2: Secondary endpoint data
Atorvastatin 
(n=30)
Placebo 
(n=30)
Leg pain 2 (7%) 0
Raised creatine kinase level* 1 (3%) 2 (7%)
Headache 3 (10%) 0
Diarrhoea 3 (10%) 0
Abdominal discomfort 1 (3%) 1 (3%)
Abnormal liver-function tests 1 (3%) 0
Haematuria 1 (3%) 0
Two patients had more than one adverse event. *Greater than two times the 
upper limit of normal.
Table 3: Adverse events
Articles
www.thelancet.com/respiratory   Vol 2   June 2014 461
atorvastatin. An association was noted in the atorvastatin 
group between reduced C-reactive protein and increased 
LCQ score. Also, a link was reported between statin 
treatment and frequency of exacerbations, with a 
decrease in relative risk noted in patients with two or 
more exacerbations. Statins had no eﬀ ect on spirometric 
ﬁ ndings, airway inﬂ ammation, bacterial colonisation or 
load, or quality of life during the study. Subanalyses 
based on adherence to treatment accorded with the main 
study ﬁ ndings.
Systemic amounts of interleukin 8 fell after 6 months 
of atorvastatin. Interleukin 8 and leukotriene B4 account 
for most of the chemotactic activity of bronchiectatic 
lung secretions.25 However, no reduction was noted in 
amounts of interleukin 8 in sputum; hence, we are 
unable to correlate the reduction in systemic interleukin 8 
to other ﬁ ndings in the study.
Immunomodulatory eﬀ ects of statins have been studied 
in other chronic lung disorders. Wang and colleagues26 
studied patients with chronic obstructive pulmonary 
disease (COPD) and showed an association between 
previous use of a statin and fewer exacerbations needing 
admission. Furthermore, long-term (more than 2 years) 
statin use led to a 39% decrease in risk of death in 
individuals with COPD.27 In a large study of 501 patients 
undergoing a lung transplant, Li and coworkers28 showed 
strong links between postoperative statin administration 
and an increase in survival, maintenance of graft-lung 
function, and slowing of the onset of bronchiolitis 
obliterans.
In our study, we recorded an increase in the number 
and proportion of apoptotic neutrophils, a decrease in the 
proportion of viable neutrophils, and a reduction in the 
total number of neutrophils obtained from sputum of 
patients at the end of 6 months of atorvastatin treatment. 
We postulate that this fall in the overall number of 
neutrophils might be related to the altered lifespan of 
these white-blood cells in response to statin treatment. 
In patients with bronchiectasis, prolonged neutrophil 
persis tence promotes excess airway inﬂ ammation.21 
A key role exists for apoptosis—or programmed cell 
death—in the regulation of inﬂ ammation and the host-
immune response.29 Although neutrophils seem to be 
committed to death via apoptosis, the lifespan and 
functional activity of mature neutrophils can be extended 
substantially by proinﬂ ammatory cytokines, including 
granulocyte colony-stimulating factor, granulocyte-
macrophage colony-stimulating factor, interferon γ, 
tumour necrosis factor α, and interleukin 2.29 By contrast, 
we have shown that neutrophil apoptosis can be induced 
by treatment with agents such as cyclin-dependent kinase 
inhibitors, promoting the resolution of inﬂ ammation.30,31 
Further more, in-vivo models of pneumococcal infection 
show that induction of apoptosis of neutrophils stimulates 
resolution of inﬂ ammation and accelerates recovery.32 
In human cancer cell lines and murine non-cancer cells,33 
statins reduced amounts of the antiapoptotic protein 
BCL2 and increased apoptosis and cell death. Statins also 
enhance eﬀ erocytosis (the process of removing dead cells 
and a key regulator of inﬂ ammation) in vitro and in vivo, 
which could have an important therapeutic role in diseases 
in which this process is impaired.34
The role of statins in augmenting apoptosis of 
neutrophils in the airways, or the mechanism by which 
statins increase apoptotic neutrophils in the sputum of 
patients with bronchiectasis, remains to be investigated. 
However, the processes of switching oﬀ  activated 
neutrophils and inducing apoptosis have therapeutic 
potential for bronchiectasis by promoting resolution of 
inﬂ ammation.
In animal models of sepsis,35 statins reduced 
endothelial dysfunction and had antithrombotic eﬀ ects 
that improved outcome. We recorded no adverse eﬀ ects 
of statins on viable bacterial load in sputum.
Compared with individuals assigned placebo, fewer 
patients allocated atorvastatin had two or more 
exacerbations; this diﬀ erence was not signiﬁ cant, but our 
study was not powered for this endpoint. Large 
multicentre studies are needed for assessment of 
exacerbations as the primary endpoint.
We did not see a reduction in the amounts of 
myeloperoxidase or free elastase in sputum, as might be 
expected. Apoptotic neutrophils would be expected to 
maintain membrane integrity until clearance and have 
diminished ability to degranulate, generate a respiratory 
burst, or undergo shape changes in response to external 
stimuli.36 However, release of these granule contents 
could take place before the induction of apoptosis. 
Our results are similar to those of Llewellyn-Jones and 
Panel: Research in context
Systematic review
We did a systematic review of PubMed, Medline, and Embase 
before November, 2010, with the terms: “bronchiectasis”, 
“COPD”, “emphysema”, “pneumonia”, “atorvastatin” or 
“statin”, and “randomized control trial”. We included all 
published reports but restricted our search to those published 
in English. We retrieved no positive results. To the best of our 
knowledge, no previous studies assessing the role of statins 
in bronchiectasis have been undertaken.
Interpretation
6 months of treatment with atorvastatin improved cough, 
assessed by the Leicester Cough Questionnaire score, in 
patients with bronchiectasis. The number of apoptotic 
neutrophils in the airways was increased with statins, 
suggesting a potential mechanism of action of reduction of 
inﬂ ammation and resolution of inﬂ ammation. We also noted 
a non-signiﬁ cant relative risk reduction for two or more 
exacerbations, but our proof-of-concept study was not 
powered to address this endpoint. Multicentre studies are 
needed to address whether long-term statin treatment can 
reduce exacerbations.
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colleagues,37 who gave indometacin 75 mg per day to 
nine patients with clinically stable bronchiectasis. Pre-
treatment with indometacin led to a reduction in 
neutrophil chemotaxis but had no eﬀ ect on sputum 
myeloperoxidase or free elastase activity, suggesting that 
these measurements in sputum might not reﬂ ect 
neutrophil numbers in the airways accurately. Further 
mechanistic studies will be needed to assess the 
immunomodulatory eﬀ ects of statins on neutrophils.
Published work supports long-term anti-infective 
treatments in patients with bronchiectasis and, 
possibly, an anti-inﬂ ammatory approach with macrolides. 
Researchers on four randomised controlled trials have 
used a macrolide (three studies of azithromycin and one 
of erythromycin) as an anti-inﬂ ammatory agent in 
patients with bronchiectasis.38-41 Findings of all studies 
showed that use of macrolides for 6–24 months, either as 
a full dose or a lower maintenance dose, led to a decrease 
in the frequency of exacerbations in bronchiectasis. 
To the best of our knowledge, our study is the ﬁ rst to 
investigate the role of statins as a potential anti-
inﬂ ammatory treatment in bronchiectasis (panel).
A major risk factor of long-term statin use is myositis 
and abnormal liver-function tests.42 In our study, we used 
the maximum dose of atorvastatin and, hence, we 
anticipated a high frequency of side-eﬀ ects. Six patients 
in the atorvastatin group withdrew from the study, versus 
one in the placebo group; the most common cause of 
dropout was headache and diarrhoea. No withdrawals 
were attributable to myositis, but abnormal liver-function 
tests led to one dropout. The only withdrawal from the 
placebo group was for personal reasons. Thus, 24 patients 
assigned atorvastatin were able to tolerate the high dose 
(80 mg) and complete the full 6 months of treatment. 
Liver function needs to be tested when patients begin 
treatment with statins, and it should be checked after 
3 months and at 1 year or earlier if any indication to do so 
arises. Patients should be encouraged to report symptoms 
of myositis, and monitoring of creatine kinase will be 
needed after the initial report.42
One limitation of our proof-of-concept study is that the 
study was not powered for any of the secondary 
endpoints. A second limitation is that we did not 
undertake exact matching of active treatment and placebo 
tablets. However, all researchers were unaware of 
treatment assignments because the Bronchiectasis Clinic 
pharmacy dispensed the randomly allocated drugs. 
Furthermore, we have no reason to believe that patients 
were aware of their treatment assignment. Although 
ﬁ xed-block random isation was used, investigators were 
not aware of the treatment assignment because the 
allocation was done by an external source (NHS Tayside). 
A third limitation is that some patients were former 
smokers, but we excluded individuals with a history of 
more than 15 pack-years and evidence of substantial 
emphysema on chest CT, making clinically signiﬁ cant 
COPD unlikely.
In conclusion, 6 months of treatment with atorvastatin 
improved cough in patients with bronchiectasis. 
The number of apoptotic neutrophils in the airways 
increased with atorvastatin, suggesting possible lessening 
of inﬂ ammation and promotion of resolution, thereby 
reducing cough. Although the mechanism for cough 
reduction is not clear, we postulate that long-term statin 
use will enhance apoptosis of sputum neutrophils, 
thereby promoting resolution of inﬂ ammation. Multi-
centre studies are now needed to assess whether long-
term statin treatment can reduce the frequency of 
exacerbations in patients with bronchiectasis. Moreover, 
future work should assess statin treatment in patients 
with severe bronchiectasis who are colonised chronically 
with P aeruginosa.
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